<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>GRASTEK- phleum pratense pollen tablet </strong><br>Merck Sharp &amp; Dohme Corp.<br></p></div>
<div id="Highlights" class="Highlights"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1>HIGHLIGHTS OF PRESCRIBING INFORMATION</h1>
<div class="HighlightsDisclaimer">These highlights do not include all the information needed to use GRASTEK safely and effectively. See full prescribing information for GRASTEK.<br><br>GRASTEK<span class="Sup">®</span> (Timothy Grass Pollen Allergen Extract)<br>Tablet for Sublingual Use<br>Initial U.S. Approval: 2014</div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">GRASTEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer GRASTEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#s4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div></div>
<div class="Warning"><div>
<h1 class="Warning">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></h1>
<h1 class="Warning"><span class="Bold Italics">See full prescribing information for complete boxed warning.</span></h1>
<ul class="Disc">
<li><span class="Bold">GRASTEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer GRASTEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#s4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div></div>
<div class="HighlightSection">
<h1 class="Highlights"><span>INDICATIONS AND USAGE</span></h1>
<div><p class="Highlighta">GRASTEK is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> confirmed by positive skin test or <span class="Italics">in vitro</span> testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age. (<a href="#s1">1</a>) </p></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE AND ADMINISTRATION</span></h1>
<div>
<p class="Highlighta"><span class="Bold">For sublingual use only.</span> (<a href="#S2">2</a>) </p>
<ul class="Disc">
<li>One tablet daily. (<a href="#s2.1">2.1</a>)</li>
<li>Initiate treatment at least 12 weeks before the expected onset of each grass pollen season and continue treatment throughout the season. For sustained effectiveness for one grass pollen season after cessation of treatment, GRASTEK may be taken daily for three consecutive years. (<a href="#s2.2">2.2</a>)</li>
<li>Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute. (<a href="#s2.2">2.2</a>)</li>
<li>Administer the first dose of GRASTEK under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#s2.2">2.2</a>)</li>
</ul>
</div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>DOSAGE FORMS AND STRENGTHS</span></h1>
<div><ul class="Disc"><li>Tablet, 2800 Bioequivalent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Units (BAUs) (<a href="#s3">3</a>)</li></ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>CONTRAINDICATIONS</span></h1>
<div><ul class="Disc">
<li>Severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#s4">4</a>)</li>
<li>History of any severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> or any severe local reaction to sublingual allergen immunotherapy. (<a href="#s4">4</a>)</li>
<li>A history of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>. (<a href="#s4">4</a>)</li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the inactive ingredients contained in this product. (<a href="#s4">4</a>)</li>
</ul></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>WARNINGS AND PRECAUTIONS</span></h1>
<div><ul class="Disc">
<li>Inform patients of the signs and symptoms of serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and instruct them to seek immediate medical care and discontinue therapy should any of these occur. (<a href="#s5.1">5.1</a>)</li>
<li>In case of oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> or <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, stop treatment with GRASTEK to allow complete healing of the oral cavity. (<a href="#s5.7">5.7</a>)</li>
</ul></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
<div></div>
</div>
<div class="HighlightSection">
<h1 class="Highlights"><span>ADVERSE REACTIONS</span></h1>
<div>
<ul class="Disc"><li>Adverse reactions reported in ≥5% of patients were: ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>. (<a href="#s6">6</a>) </li></ul>
<br><p class="Highlighta"><span class="Bold">To report SUSPECTED ADVERSE REACTIONS, contact Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., at 1-877-888-4231 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.</span> </p>
</div>
<div>
<div></div>
<div></div>
</div>
<div>
<div></div>
<div></div>
</div>
</div>
<div>
<div><div></div></div>
<div></div>
<div></div>
</div>
<div></div>
<div><div></div></div>
<div><div></div></div>
<div>
<div>
<div></div>
<div></div>
</div>
<div><div></div></div>
</div>
<div><div></div></div>
<div>
<div></div>
<div></div>
<div></div>
</div>
<div></div>
<div></div>
<div></div>
<div></div>
<p class="HighlightsSeeReference">See 17 for PATIENT COUNSELING INFORMATION and Medication Guide.</p>
<p class="HighlightsRevision">Revised: 6/2014</p>
</div></td></tr></table></div>
<div id="Index" class="Index"><table cellspacing="5" cellpadding="5" width="100%" style="table-layout:fixed"><tr><td align="left" valign="top"><div>
<h1 class="Colspan">FULL PRESCRIBING INFORMATION: CONTENTS<a href="#footnote-content" name="footnote-reference-content">*</a>
</h1>
<h1><a href="#section-1" class="toc"><span class="Emphasis">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></span></a></h1>
<h1><a href="#section-1" class="toc">1 INDICATIONS AND USAGE</a></h1>
<h1><a href="#section-2" class="toc">2 DOSAGE AND ADMINISTRATION</a></h1>
<h2><a href="#section-2.1" class="toc">2.1	Dose</a></h2>
<h2><a href="#section-2.2" class="toc">2.2	Administration</a></h2>
<h1><a href="#section-3" class="toc">3 DOSAGE FORMS AND STRENGTHS</a></h1>
<h1><a href="#section-4" class="toc">4 CONTRAINDICATIONS</a></h1>
<h1><a href="#section-5" class="toc">5 WARNINGS AND PRECAUTIONS</a></h1>
<h2><a href="#section-5.1" class="toc">5.1	Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></a></h2>
<h2><a href="#section-5.2" class="toc">5.2	Epinephrine</a></h2>
<h2><a href="#section-5.3" class="toc">5.3	Upper Airway Compromise</a></h2>
<h2><a href="#section-5.4" class="toc">5.4	Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></a></h2>
<h2><a href="#section-5.5" class="toc">5.5	<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></a></h2>
<h2><a href="#section-5.6" class="toc">5.6	Concomitant Allergen Immunotherapy</a></h2>
<h2><a href="#section-5.7" class="toc">5.7	Oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></a></h2>
<h1><a href="#section-6" class="toc">6 ADVERSE REACTIONS</a></h1>
<h2><a href="#section-6.1" class="toc">6.1	Clinical Trials Experience</a></h2>
<h2><a href="#section-6.2" class="toc">6.2	Postmarketing Experience</a></h2>
<h1><a href="#section-7" class="toc">8 USE IN SPECIFIC POPULATIONS</a></h1>
<h2><a href="#section-7.1" class="toc">8.1 Pregnancy</a></h2>
<h2><a href="#section-7.2" class="toc">8.3 Nursing Mothers</a></h2>
<h2><a href="#section-7.3" class="toc">8.4 Pediatric Use</a></h2>
<h2><a href="#section-7.4" class="toc">8.5 Geriatric Use</a></h2>
<h1><a href="#section-8" class="toc">11 DESCRIPTION</a></h1>
<h1><a href="#section-9" class="toc">12 CLINICAL PHARMACOLOGY</a></h1>
<h2><a href="#section-9.1" class="toc">12.1 Mechanism of Action</a></h2>
<h1><a href="#section-10" class="toc">13 NONCLINICAL TOXICOLOGY</a></h1>
<h2><a href="#section-10.1" class="toc">13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</a></h2>
<h1><a href="#section-11" class="toc">14 CLINICAL STUDIES</a></h1>
<h2><a href="#section-11.1" class="toc">14.1	First Season Efficacy</a></h2>
<h2><a href="#section-11.2" class="toc">14.2	Sustained Effect</a></h2>
<h1><a href="#section-12" class="toc">16 HOW SUPPLIED/STORAGE AND HANDLING</a></h1>
<h1><a href="#section-13" class="toc">17 PATIENT COUNSELING INFORMATION</a></h1>
<dl class="Footnote">
<dt><a href="#footnote-reference-content" name="footnote-content">*</a></dt>
<dd>Sections or subsections omitted from the full prescribing information are not listed.</dd>
</dl>
</div></td></tr></table></div>
<div class="Contents">
<h1>FULL PRESCRIBING INFORMATION</h1>
<div class="Section" data-sectionCode="48780-1">
<a name="DLDE"></a><a name="section-1"></a><p></p>
</div>
<div class="Warning">
<a name="BOX"></a><a name="section-1"></a><p></p>
<h1><span class="Emphasis">WARNING: SEVERE <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">ALLERGIC REACTIONS</span></span></h1>
<ul class="Disc">
<li><span class="Bold">GRASTEK can cause life-threatening <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> such as <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> and severe laryngopharyngeal restriction. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Do not administer GRASTEK to patients with severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>. (<a href="#s4">4</a>)</span></li>
<li><span class="Bold">Observe patients in the office for at least 30 minutes following the initial dose. (<a href="#s5.1">5.1</a>)</span></li>
<li><span class="Bold">Prescribe auto-injectable epinephrine, instruct and train patients on its appropriate use, and instruct patients to seek immediate medical care upon its use. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients with certain underlying medical conditions that may reduce their ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. (<a href="#s5.2">5.2</a>)</span></li>
<li><span class="Bold">GRASTEK may not be suitable for patients who may be unresponsive to epinephrine or inhaled bronchodilators, such as those taking beta-blockers. (<a href="#s5.2">5.2</a>)</span></li>
</ul>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="S1"></a><a name="section-1"></a><p></p>
<h1>1 INDICATIONS AND USAGE</h1>
<p class="First">GRASTEK<span class="Sup">®</span> is an allergen extract indicated as immunotherapy for the treatment of grass pollen-induced <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> confirmed by positive skin test or <span class="Italics">in vitro</span> testing for pollen-specific IgE antibodies for Timothy grass or cross-reactive grass pollens. GRASTEK is approved for use in persons 5 through 65 years of age.</p>
<p>GRASTEK is not indicated for the immediate relief of allergic symptoms.</p>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="S2"></a><a name="section-2"></a><p></p>
<h1>2 DOSAGE AND ADMINISTRATION</h1>
<p class="First"><span class="Bold">For sublingual use only. </span></p>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.1"></a><a name="section-2.1"></a><p></p>
<h2>2.1	Dose</h2>
<p class="First">One GRASTEK tablet daily.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s2.2"></a><a name="section-2.2"></a><p></p>
<h2>2.2	Administration</h2>
<p class="First">Administer the first dose of GRASTEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases. After receiving the first dose of GRASTEK, observe the patient for at least 30 minutes to monitor for signs or symptoms of a severe systemic or a severe local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. If the patient tolerates the first dose, the patient may take subsequent doses at home.</p>
<dl>
<dt> </dt>
<dd>Administer GRASTEK to children under adult supervision.</dd>
<dt> </dt>
<dd>Take the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit after carefully removing the foil with dry hands.</dd>
<dt> </dt>
<dd>Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.</dd>
<dt> </dt>
<dd>Wash hands after handling the tablet. </dd>
<dt> </dt>
<dd>Do not take the tablet with food or beverage. Food or beverage should not be taken for the following 5 minutes after taking the tablet.</dd>
</dl>
<p>Initiate treatment at least 12 weeks before the expected onset of each grass pollen season and continue treatment throughout the season. For sustained effectiveness for one grass pollen season after cessation of treatment, GRASTEK may be taken daily for three consecutive years (including the intervals between the grass pollen seasons). The safety and efficacy of initiating treatment in season have not been established.</p>
<p>Data regarding the safety of restarting treatment after missing a dose of GRASTEK are limited. In the clinical trials, treatment interruptions for up to seven days were allowed.</p>
<p>Prescribe auto-injectable epinephrine to patients prescribed GRASTEK and instruct them in the proper use of emergency self-injection of epinephrine <span class="Italics">[See <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span>.</p>
</div>
</div>
<div class="Section" data-sectionCode="43678-2">
<a name="S3"></a><a name="section-3"></a><p></p>
<h1>3 DOSAGE FORMS AND STRENGTHS</h1>
<p class="First">GRASTEK is available as 2800 Bioequivalent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Unit (BAU) tablets that are white to off-white, circular with a debossed round detail on one side.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="S4"></a><a name="section-4"></a><p></p>
<h1>4 CONTRAINDICATIONS</h1>
<p class="First">GRASTEK is contraindicated in patients with:</p>
<ul>
<li>Severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>A history of any severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span></li>
<li>A history of any severe local reaction after taking any sublingual allergen immunotherapy</li>
<li>A history of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span></li>
<li><span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Hypersensitivity</span> to any of the inactive ingredients [gelatin, mannitol and sodium hydroxide] contained in this product <span class="Italics">[See <a href="#s11">Description (11)</a>]</span>.</li>
</ul>
</div>
<div class="Section" data-sectionCode="43685-7">
<a name="S5"></a><a name="section-5"></a><p></p>
<h1>5 WARNINGS AND PRECAUTIONS</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.1"></a><a name="section-5.1"></a><p></p>
<h2>5.1	Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></h2>
<p class="First">GRASTEK can cause <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span> which may be life-threatening. In addition, GRASTEK can cause severe local reactions, including laryngopharyngeal <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span>, which can compromise breathing and be life-threatening. Educate patients to recognize the signs and symptoms of these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> and instruct them to seek immediate medical care and discontinue therapy should any of these occur. <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic reactions</span> may require treatment with epinephrine. <span class="Italics">[See <a href="#s5.2">Warnings and Precautions (5.2)</a>]</span></p>
<p>Administer the initial dose of GRASTEK in a healthcare setting under the supervision of a physician with experience in the diagnosis and treatment of allergic diseases and prepared to manage a life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. Observe patients in the office for at least 30 minutes following the initial dose of GRASTEK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.2"></a><a name="section-5.2"></a><p></p>
<h2>5.2	Epinephrine</h2>
<p class="First">Prescribe auto-injectable epinephrine to patients receiving GRASTEK. Instruct patients to recognize the signs and symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> and in the proper use of emergency auto-injectable epinephrine. Instruct patients to seek immediate medical care upon use of auto-injectable epinephrine and to stop treatment with GRASTEK. <span class="Italics">[See <a href="#s17">Patient Counseling Information (17)</a>.]</span></p>
<p>See the epinephrine package insert for complete information.</p>
<p>GRASTEK may not be suitable for patients with certain medical conditions that may reduce the ability to survive a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or increase the risk of adverse reactions after epinephrine administration. Examples of these medical conditions include but are not limited to: markedly compromised lung function (either chronic or acute), <span class="product-label-link" type="condition" conceptid="315296" conceptname="Preinfarction syndrome">unstable angina</span>, recent <span class="product-label-link" type="condition" conceptid="4329847" conceptname="Myocardial infarction">myocardial infarction</span>, significant <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">arrhythmia</span>, and <span class="product-label-link" type="condition" conceptid="4269635" conceptname="Hypertensive episode">uncontrolled hypertension</span>.</p>
<p>GRASTEK may not be suitable for patients who are taking medications that can potentiate or inhibit the effect of epinephrine. These medications include:</p>
<dl>
<dt> </dt>
<dd>
<span class="Underline">Beta-adrenergic blockers</span>: Patients taking beta-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Specifically, beta-adrenergic blockers antagonize the cardiostimulating and bronchodilating effects of epinephrine.</dd>
<dt> </dt>
<dd>
<span class="Underline">Alpha-adrenergic blockers, ergot alkaloids</span>: Patients taking alpha-adrenergic blockers may be unresponsive to the usual doses of epinephrine used to treat serious systemic reactions, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Specifically, alpha-adrenergic blockers antagonize the vasoconstricting and hypertensive effects of epinephrine. Similarly, ergot alkaloids may reverse the pressor effects of epinephrine.</dd>
<dt> </dt>
<dd>
<span class="Underline">Tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors and certain antihistamines</span>: The adverse effects of epinephrine may be potentiated in patients taking tricyclic antidepressants, levothyroxine sodium, monoamine oxidase inhibitors, and the antihistamines chlorpheniramine, and diphenhydramine.</dd>
<dt> </dt>
<dd>
<span class="Underline">Cardiac glycosides, diuretics</span>: Patients who receive epinephrine while taking cardiac glycosides or diuretics should be observed carefully for the development of <span class="product-label-link" type="condition" conceptid="44784217" conceptname="Cardiac arrhythmia">cardiac arrhythmias</span>.</dd>
</dl>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.3"></a><a name="section-5.3"></a><p></p>
<h2>5.3	Upper Airway Compromise</h2>
<p class="First">GRASTEK can cause local reactions in the mouth or throat that could compromise the upper airway <span class="Italics">[See <a href="#s6.1">Adverse Reactions (6.1</a> and <a href="#s6.2">6.2)</a>].</span> Consider discontinuation of GRASTEK in patients who experience persistent and escalating adverse reactions in the mouth or throat.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.4"></a><a name="section-5.4"></a><p></p>
<h2>5.4	Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">Esophagitis</span></h2>
<p class="First">Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> has been reported in association with sublingual tablet immunotherapy <span class="Italics">[See <a href="#s4">Contraindications (4)</a> and <a href="#s6.2">Adverse Reactions (6.2)</a>].</span> Discontinue GRASTEK and consider a diagnosis of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> in patients who experience severe or persistent gastro-esophageal symptoms including <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.5"></a><a name="section-5.5"></a><p></p>
<h2>5.5	<span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></h2>
<p class="First">GRASTEK has not been studied in subjects with moderate or severe <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> or any subjects who required daily medication to treat <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>.</p>
<p>Withhold immunotherapy with GRASTEK if the patient is experiencing an acute <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbation. Reevaluate patients who have recurrent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbations and consider discontinuation of GRASTEK.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.6"></a><a name="section-5.6"></a><p></p>
<h2>5.6	Concomitant Allergen Immunotherapy</h2>
<p class="First">GRASTEK has not been studied in subjects who are receiving concomitant allergen immunotherapy. Concomitant dosing with other allergen immunotherapy may increase the likelihood of local or systemic adverse reactions to either subcutaneous or sublingual allergen immunotherapy.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s5.7"></a><a name="section-5.7"></a><p></p>
<h2>5.7	Oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">Inflammation</span></h2>
<p class="First">Stop treatment with GRASTEK to allow complete healing of the oral cavity in patients with oral <span class="product-label-link" type="condition" conceptid="4053015" conceptname="Inflammation">inflammation</span> (e.g., oral <span class="product-label-link" type="condition" conceptid="132703" conceptname="Lichen planus">lichen planus</span>, <span class="product-label-link" type="condition" conceptid="4094986" conceptname="Ulcer of mouth">mouth ulcers</span> or <span class="product-label-link" type="condition" conceptid="29735" conceptname="Candidiasis of mouth">thrush</span>) or oral <span class="product-label-link" type="condition" conceptid="4029919" conceptname="Wound">wounds</span>, such as those following oral surgery or dental extraction.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="S6"></a><a name="section-6"></a><p></p>
<h1>6 ADVERSE REACTIONS</h1>
<p class="First">Adverse reactions reported in ≥5% of patients were: ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, and <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.1"></a><a name="section-6.1"></a><p></p>
<h2>6.1	Clinical Trials Experience</h2>
<p class="First">Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.1"></a><p></p>
<p class="First"><span class="Italics">Adults</span></p>
<p>The safety data described below are based on 6 clinical trials which randomized 3589 subjects 18 through 65 years of age with Timothy grass pollen induced <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>, including 1669 subjects who were exposed to at least one dose of GRASTEK. Of the subjects treated with GRASTEK, 25% had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 80% were sensitized to other allergens in addition to grass. The subject population was 88% White, 7% African American, and 3% Asian. Subjects were 52% male, and 88% of subjects were between 18 and 50 years of age. Subject demographics in placebo-treated subjects were similar to the active group.</p>
<p>The most common adverse reactions reported in subjects treated with GRASTEK were oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (26.7% vs 3.5% placebo), <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span> (22.6% vs 2.8%), ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (12.5% vs 1.1%) and mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (11.1% vs 0.8%). The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to GRASTEK or placebo was 4.9% and 0.9%, respectively. The most common adverse reactions that led to study discontinuation in subjects who were exposed to GRASTEK were <span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">pharyngeal edema</span> and oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>.</p>
<p>Seven adult subjects (7/1669; 0.4%) who received GRASTEK experienced treatment-related <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reactions</span> that led to discontinuation of GRASTEK in four out of the seven subjects.</p>
<ul>
<li>Five of the seven subjects had reactions on Day 1 of treatment with GRASTEK. Symptoms included <span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">swelling of lips</span>/mouth; oral/pharyngeal <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>; ear <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>, <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>, <span class="product-label-link" type="condition" conceptid="432730" conceptname="Difficulty speaking">dysphonia</span>, <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, and <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>. Three of the five subjects received treatment with epinephrine and antihistamines, and one of the three also received oral corticosteroids. One of the five subjects who had a reaction on Day 1 of treatment with GRASTEK also had a reaction on Day 2 of treatment with GRASTEK. Symptoms on Day 2 included oral <span class="product-label-link" type="condition" conceptid="4235891" conceptname="Burning sensation">burning sensation</span>; <span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">rhinorrhea</span>; and <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>.</li>
<li>One of the seven subjects had a reaction on Day 2 after tolerating treatment with GRASTEK on Day 1. Symptoms included <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> of the lower lip, <span class="product-label-link" type="condition" conceptid="4002232" conceptname="Epigastric discomfort">epigastric discomfort</span> and <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>.</li>
<li>One of the seven subjects developed <span class="product-label-link" type="condition" conceptid="4034235" conceptname="Tight chest">chest tightness</span> and <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span> on Day 42 of treatment with GRASTEK.</li>
</ul>
<p>Adverse reactions reported in ≥1% of subjects treated with GRASTEK are shown in Table 1.</p>
<a name="table1"></a><table width="75%">
<caption><span>Table 1: Adverse Reactions Reported in ≥1% of Adults Treated with GRASTEK</span></caption>
<col align="left" valign="top" width="34%">
<col align="center" valign="top" width="36%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">
<br>Adverse Reaction</th>
<th class="Rrule" align="center">
<br>GRASTEK<br>(N=1669)</th>
<th class="Rrule" align="center">
<br>PLACEBO<br>(N=1645)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">2.1%</td>
<td class="Rrule" align="center">1.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Ear and Labyrinth Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">12.5%</td>
<td class="Rrule" align="center">1.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></td>
<td class="Rrule" align="center">22.6%</td>
<td class="Rrule" align="center">2.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">Pharyngeal edema</span></td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4010026" conceptname="Pharyngeal dryness">Dry throat</span></td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">1.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nasal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">1.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">26.7%</td>
<td class="Rrule" align="center">3.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">11.1%</td>
<td class="Rrule" align="center">0.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">Paraesthesia oral</span></td>
<td class="Rrule" align="center">9.8%</td>
<td class="Rrule" align="center">2.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">5.7%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">Lip swelling</span></td>
<td class="Rrule" align="center">4.0%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen tongue</span></td>
<td class="Rrule" align="center">2.8%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Dyspepsia</span></td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">Hypoesthesia oral</span></td>
<td class="Rrule" align="center">2.3%</td>
<td class="Rrule" align="center">1.0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.9%</td>
<td class="Rrule" align="center">0.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4150136" conceptname="Discomfort in mouth">Oral discomfort</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral mucosal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Rrule" align="center">1.5%</td>
<td class="Rrule" align="center">0.6%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lip <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="436147" conceptname="Glossitis">Glossitis</span></td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="432941" conceptname="Disorder of tongue">Tongue disorder</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4217627" conceptname="Edema of the tongue">Tongue edema</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">Glossodynia</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.3%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Palatal <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">1.0%</td>
<td class="Rrule" align="center">0.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">Pruritus</span></td>
<td class="Rrule" align="center">2.4%</td>
<td class="Rrule" align="center">1.0%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Rrule" align="center">1.7%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">Fatigue</span></td>
<td class="Rrule" align="center">1.4%</td>
<td class="Rrule" align="center">0.4%</td>
</tr>
</tbody>
</table>
<p>Adverse reactions of interest that occurred in ≤1% of GRASTEK recipients include <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span> and <span class="product-label-link" type="condition" conceptid="318800" conceptname="Gastroesophageal reflux disease">gastroesophageal reflux</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.1.2"></a><p></p>
<p class="First"><span class="Italics">Pediatrics</span></p>
<p>Safety data are based on 3 clinical trials which randomized 881 subjects between 5 and 17 years of age with grass pollen induced <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span>. Overall, 445 subjects received at least one dose of GRASTEK. Of the subjects treated with GRASTEK, 31% had mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 86% were sensitized to other allergens in addition to grass. The subject population was 86% White, 7% African American and 3% multi-racial. The majority (66%) of subjects were male. The mean age of subjects was 11.7 years. Subject demographics in placebo-treated subjects were similar to the active group.</p>
<p>The most common adverse reactions in pediatric subjects treated with GRASTEK were oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span> (24.4% vs 2.1% placebo), <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span> (21.3% vs 2.5%) and mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span> (9.8% vs 0.2%). The percentage of subjects who discontinued from the clinical trials because of an adverse reaction while exposed to GRASTEK or placebo was 6.3% and 0.7%, respectively.</p>
<p>One pediatric subject (1/447; 0.2%) who received GRASTEK experienced a treatment-related <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">systemic allergic reaction</span> consisting of lip <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, slight <span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">dysphagia</span> due to the sensation of a lump in the throat, and intermittent <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span> which was of moderate intensity on Day 1. The subject was treated with epinephrine, recovered, and was discontinued from the trial.</p>
<p>Adverse reactions reported in ≥1% of subjects treated with GRASTEK are shown in Table 2.</p>
<a name="table2"></a><table width="75%">
<caption><span>Table 2: Adverse Reactions Reported in ≥1% of Pediatric Subjects Treated with GRASTEK</span></caption>
<col align="left" valign="top" width="35%">
<col align="center" valign="top" width="35%">
<col align="center" valign="top" width="30%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">
<br>Adverse Reaction</th>
<th class="Rrule" align="center">
<br>GRASTEK<br>(N=447)</th>
<th class="Rrule" align="center">
<br>PLACEBO<br>(N=434)</th>
</tr></thead>
<tbody>
<tr class="First">
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="376337" conceptname="Disorder of nervous system">Nervous System Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">Headache</span></td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">1.8%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Ear and Labyrinth Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left">Ear <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">7.2%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="375252" conceptname="Disorder of eye">Eye Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">Eye pruritus</span></td>
<td class="Rrule" align="center">3.4%</td>
<td class="Rrule" align="center">2.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Respiratory, Thoracic and <span class="product-label-link" type="condition" conceptid="440142" conceptname="Disorder of mediastinum">Mediastinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">Throat irritation</span></td>
<td class="Rrule" align="center">21.3%</td>
<td class="Rrule" align="center">2.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oropharyngeal <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span></td>
<td class="Rrule" align="center">4.0%</td>
<td class="Rrule" align="center">1.4%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4054846" conceptname="Red throat">Pharyngeal erythema</span></td>
<td class="Rrule" align="center">3.6%</td>
<td class="Rrule" align="center">0.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4056883" conceptname="Edema of pharynx">Pharyngeal edema</span></td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">Cough</span></td>
<td class="Rrule" align="center">2.7%</td>
<td class="Rrule" align="center">1.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span></td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Nasal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">Nasal congestion</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">Sneezing</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.7%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics"><span class="product-label-link" type="condition" conceptid="4302537" conceptname="Digestive system finding">Gastrointestinal Disorders</span></span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">24.4%</td>
<td class="Rrule" align="center">2.1%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Mouth <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span></td>
<td class="Rrule" align="center">9.8%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Tongue <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">9.2%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="44783305" conceptname="Lip swelling">Lip swelling</span></td>
<td class="Rrule" align="center">7.2%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4015676" conceptname="Circumoral paresthesia">Paraesthesia oral</span></td>
<td class="Rrule" align="center">5.4%</td>
<td class="Rrule" align="center">1.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Oral mucosal <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema</span></td>
<td class="Rrule" align="center">4.9%</td>
<td class="Rrule" align="center">0.9%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left">Lip <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span></td>
<td class="Rrule" align="center">2.9%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4222234" conceptname="Tongue swelling">Swollen tongue</span></td>
<td class="Rrule" align="center">2.5%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31317" conceptname="Dysphagia">Dysphagia</span></td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4150136" conceptname="Discomfort in mouth">Oral discomfort</span></td>
<td class="Rrule" align="center">1.6%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="138455" conceptname="Stomatitis">Stomatitis</span></td>
<td class="Rrule" align="center">1.3%</td>
<td class="Rrule" align="center">0%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4009388" conceptname="Perioral numbness">Hypoesthesia oral</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="441334" conceptname="Glossodynia">Glossodynia</span></td>
<td class="Rrule" align="center">1.1%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">Skin and Subcutaneous Tissue Disorders</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">Urticaria</span></td>
<td class="Rrule" align="center">1.8%</td>
<td class="Rrule" align="center">0.2%</td>
</tr>
<tr>
<td class="Lrule Rrule" align="left"><span class="Bold Italics">General Disorders and Administration Site Conditions</span></td>
<td class="Rrule" align="center"></td>
<td class="Rrule" align="center"></td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">Chest discomfort</span></td>
<td class="Rrule" align="center">2.0%</td>
<td class="Rrule" align="center">0.5%</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s6.2"></a><a name="section-6.2"></a><p></p>
<h2>6.2	Postmarketing Experience</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.1"></a><p></p>
<p class="First"><span class="Italics">Postmarketing Safety Studies</span></p>
<p>In European post-approval studies which included 1,666 patients treated with GRASTEK (marketed under the name GRAZAX), reported serious adverse reactions assessed as related to GRASTEK use included <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic reaction</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exacerbation, <span class="product-label-link" type="condition" conceptid="4142495" conceptname="Hypophonia">hoarseness</span>, <span class="product-label-link" type="condition" conceptid="24969" conceptname="Laryngitis">laryngitis</span>, <span class="product-label-link" type="condition" conceptid="4260546" conceptname="Ulcerative stomatitis">oral ulceration</span>, and <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> exacerbation.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-6.2.2"></a><p></p>
<p class="First"><span class="Italics">Spontaneous Postmarketing Reports</span></p>
<p>The following adverse reactions have been identified during post-approval use of GRASTEK (marketed under the name GRAZAX in Europe). Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. These include: <span class="product-label-link" type="condition" conceptid="376961" conceptname="Disturbance of consciousness">altered state of consciousness</span>, <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span>, <span class="product-label-link" type="condition" conceptid="432791" conceptname="Angioedema">angioedema</span>, <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> exercise induced, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest pressure</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, difficulty speaking, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, <span class="product-label-link" type="condition" conceptid="137193" conceptname="Erythema">erythema facial</span>, face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>, <span class="product-label-link" type="condition" conceptid="4261798" conceptname="Decreased forced expiratory volume">forced expiratory volume decreased</span>, <span class="product-label-link" type="condition" conceptid="444070" conceptname="Tachycardia">heart rate increased</span>, <span class="product-label-link" type="condition" conceptid="4088122" conceptname="Heart irregular">heart rate irregular</span>, <span class="product-label-link" type="condition" conceptid="316814" conceptname="Hyperventilation">hyperventilation</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, laryngeal <span class="product-label-link" type="condition" conceptid="4090431" conceptname="Discomfort">discomfort</span>, <span class="product-label-link" type="condition" conceptid="4010025" conceptname="Painful mouth">oral pain</span>, oxygen saturation decreased, peak expiratory flow rate decreased, <span class="product-label-link" type="condition" conceptid="255848" conceptname="Pneumonia">pneumonia</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4158346" conceptname="Respiratory distress">respiratory distress</span>, <span class="product-label-link" type="condition" conceptid="4090430" conceptname="Foreign body sensation">sensation of foreign body</span>, status asthmaticus, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of neck, throat <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="443782" conceptname="Tremor">tremor</span>, <span class="product-label-link" type="condition" conceptid="4264489" conceptname="Decreased vital capacity">vital capacity decreased</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, and <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>. Included in these reports was an adult male with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> who experienced <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylactic shock</span> within two minutes of administration of GRASTEK. The patient experienced <span class="product-label-link" type="condition" conceptid="4171908" conceptname="Semicoma">depressed level of consciousness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, increased heart rate, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, and face <span class="product-label-link" type="condition" conceptid="433595" conceptname="Edema">edema</span>.</p>
<p>Eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> has been reported following treatment with GRASTEK (marketed under the name GRAZAX). The clinical details of some postmarketing reports are consistent with a drug-induced effect, including at least one case with resolution of symptoms upon discontinuation of GRASTEK, relapse after resuming GRASTEK and resolution again after discontinuation of GRASTEK.</p>
</div>
</div>
</div>
<div class="Section" data-sectionCode="43684-0">
<a name="S8"></a><a name="section-7"></a><p></p>
<h1>8 USE IN SPECIFIC POPULATIONS</h1>
<div class="Section" data-sectionCode="42228-7">
<a name="S8.1"></a><a name="section-7.1"></a><p></p>
<h2>8.1 Pregnancy</h2>
<div class="Section" data-sectionCode="34077-8">
<a name="section-7.1.1"></a><p></p>
<p class="First"><span class="Italics">Pregnancy Category B</span>: Reproductive and developmental toxicity studies performed in female mice have revealed no evidence of harm to the fetus due to GRASTEK. In these studies, the effect of Timothy grass (<span class="Italics">Phleum pratense</span>) pollen allergen extract, the active component of GRASTEK, on embryo-fetal development was evaluated. Mice were administered approximately 460,000 BAU/kg/day of Timothy grass pollen allergen extract by oral gavage on days 0 to 15 of gestation. A dose of 460,000 BAU/kg/day of Timothy grass pollen allergen extract corresponds to approximately 8,200-fold a human dose on a BAU/kg/day basis. No adverse effects on embryo-fetal development were observed. There are, however, no adequate and well-controlled studies in pregnant women. Because animal reproduction studies are not always predictive of human response, GRASTEK should be used during pregnancy only if clearly needed.</p>
<p>Because systemic and local adverse reactions with immunotherapy may be poorly tolerated during pregnancy, GRASTEK should be used during pregnancy only if clearly needed.</p>
</div>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="S8.3"></a><a name="section-7.2"></a><p></p>
<h2>8.3 Nursing Mothers</h2>
<p class="First">It is not known if GRASTEK is excreted in human milk. Because many drugs are excreted in human milk, caution should be exercised when GRASTEK is administered to a nursing woman.</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="S8.4"></a><a name="section-7.3"></a><p></p>
<h2>8.4 Pediatric Use</h2>
<p class="First">Efficacy and safety of GRASTEK have been established in children and adolescents 5 through 17 years of age.</p>
<p>The safety and efficacy in pediatric patients below 5 years of age have not been established.</p>
</div>
<div class="Section" data-sectionCode="34082-8">
<a name="S8.5"></a><a name="section-7.4"></a><p></p>
<h2>8.5 Geriatric Use</h2>
<p class="First">There is no clinical trial experience with GRASTEK in patients over 65 years of age.</p>
</div>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="S11"></a><a name="section-8"></a><p></p>
<h1>11 DESCRIPTION</h1>
<p class="First">GRASTEK tablets contain pollen allergen extract from Timothy grass (<span class="Italics">Phleum pratense</span>). GRASTEK is a sublingual tablet.</p>
<p>GRASTEK is available as a tablet of 2800 BAU of Timothy grass pollen allergen extract.</p>
<p>Inactive ingredients: gelatin NF (fish source), mannitol USP and sodium hydroxide NF.</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="S12"></a><a name="section-9"></a><p></p>
<h1>12 CLINICAL PHARMACOLOGY</h1>
<div class="Section" data-sectionCode="43679-0">
<a name="S12.1"></a><a name="section-9.1"></a><p></p>
<h2>12.1 Mechanism of Action</h2>
<p class="First">The precise mechanisms of action of allergen immunotherapy are not known.</p>
</div>
</div>
<div class="Section" data-sectionCode="43680-8">
<a name="S13"></a><a name="section-10"></a><p></p>
<h1>13 NONCLINICAL TOXICOLOGY</h1>
<div class="Section" data-sectionCode="34083-6">
<a name="S13.1"></a><a name="section-10.1"></a><p></p>
<h2>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">No studies have been performed in animals to evaluate the carcinogenic potential of GRASTEK.</p>
<p>There were no positive findings in the <span class="Italics">in vitro</span> mouse <span class="product-label-link" type="condition" conceptid="432571" conceptname="Malignant lymphoma">lymphoma</span> and the bacterial reverse mutation assays for mutagenicity using Timothy grass (<span class="Italics">Phleum pratense</span>) pollen allergen extract.</p>
<p>A fertility study in mice revealed no evidence of impaired fertility due to Timothy grass pollen allergen extract.</p>
</div>
</div>
<div class="Section" data-sectionCode="34092-7">
<a name="S14"></a><a name="section-11"></a><p></p>
<h1>14 CLINICAL STUDIES</h1>
<p class="First">The efficacy of GRASTEK in the treatment of <span class="product-label-link" type="condition" conceptid="257007" conceptname="Allergic rhinitis">allergic rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> in Timothy grass pollen allergic subjects 5 years of age and older, with or without mild <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, was evaluated during the first grass pollen season in two trials of approximately 24 weeks treatment duration. The sustained effect of GRASTEK was evaluated in one trial conducted over 5 grass pollen seasons. All three trials were randomized, double-blind, parallel group, multicenter clinical trials. Subjects had a history of grass pollen induced <span class="product-label-link" type="condition" conceptid="4320791" conceptname="Rhinitis">rhinitis</span> with or without <span class="product-label-link" type="condition" conceptid="379019" conceptname="Conjunctivitis">conjunctivitis</span> and sensitivity to Timothy grass pollen as determined by specific testing (IgE). In these three studies, subjects initiated GRASTEK or placebo approximately 12 weeks prior to the pollen season. In the long-term study, subjects received GRASTEK or placebo daily for 3 consecutive years and were followed for 2 years without treatment.</p>
<p>Efficacy was established by self-reporting of rhinoconjunctivitis daily symptom scores (DSS) and daily medication scores (DMS). Daily rhinoconjunctivitis symptoms included four nasal symptoms (<span class="product-label-link" type="condition" conceptid="4170297" conceptname="Sniffles">runny nose</span>, stuffy nose, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, and <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose), and two ocular symptoms (gritty/<span class="product-label-link" type="condition" conceptid="4254270" conceptname="Itching of eye">itchy eyes</span> and watery eyes). The rhinoconjunctivitis symptoms were measured on a scale of 0 (none) to 3 (severe). Subjects in clinical trials were allowed to take symptom-relieving medications (including systemic and topical antihistamines and topical and oral corticosteroids) as needed. The daily medication score measured the use of standard open-label <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> medications. Predefined values were assigned to each class of medication. Generally, systemic and topical antihistamines were given the lowest score, topical steroids an intermediate score, and oral corticosteroids the highest score. The sums of the DSS and DMS were combined into the Total Combined Score (TCS) which was averaged over the entire grass pollen season.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.1"></a><a name="section-11.1"></a><p></p>
<h2>14.1	First Season Efficacy</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.1"></a><p></p>
<p class="First"><span class="Underline">Adults and Children</span></p>
<p>This placebo-controlled trial evaluated 1501 subjects 5 through 65 years of age (approximately 80% were 18 years and older) comparing GRASTEK (N=752) and placebo (N=749) administered as a sublingual tablet daily for approximately 24 weeks. The subject population was 84% White, 9% African American and 4% Asian. The majority of subjects were male (52%). In this study, approximately 25% of subjects had mild, intermittent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and 85% of all subjects were sensitized to other allergens in addition to grass pollen. Subjects with a clinical history of symptomatic allergies to non-grass pollen allergens that required treatment during the grass pollen season were excluded from the studies. All treatment groups were balanced with regard to baseline characteristics.</p>
<p>Subjects treated with GRASTEK had a decrease in the TCS throughout the grass pollen season compared to placebo-treated subjects. Similarly, the DSS and DMS were decreased in subjects treated with GRASTEK compared to placebo throughout the grass pollen season, and the TCS was decreased compared to placebo during the peak grass pollen season (see <a href="#table3">Table 3</a>).</p>
<a name="table3"></a><table width="85%">
<caption><span>Table 3: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS), and Daily Medication Scores (DMS) During the Grass Pollen Season</span></caption>
<col align="left" valign="middle" width="17%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="21%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Endpoint<a name="footnote-reference-1" href="#footnote-1" class="Sup">*</a>
</th>
<th class="Rrule" align="center">GRASTEK<br>(N)<a name="footnote-reference-2" href="#footnote-2" class="Sup">†</a><br>Score<a name="footnote-reference-3" href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Placebo<br>(N)<a href="#footnote-2" class="Sup">†</a><br>Score<a href="#footnote-3" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Treatment Difference (GRASTEK – Placebo)</th>
<th class="Rrule" align="center">Difference Relative to Placebo<a name="footnote-reference-4" href="#footnote-4" class="Sup">§</a><br>Estimate <br>(95% CI)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-1" href="#footnote-reference-1">*</a></dt>
<dd>Non-parametric analysis for TCS and DSS endpoints: Parametric analysis using zero-inflated log-normal model for DMS.</dd>
<dt><a name="footnote-2" href="#footnote-reference-2">†</a></dt>
<dd>Number of subjects in analyses.</dd>
<dt><a name="footnote-3" href="#footnote-reference-3">‡</a></dt>
<dd>For TCS and DSS endpoints the group medians are reported, treatment difference and that relative to placebo is based on group medians. For DMS, the group means are reported and difference relative to placebo is based on estimated group means.</dd>
<dt><a name="footnote-4" href="#footnote-reference-4">§</a></dt>
<dd>Difference relative to placebo computed as: (GRASTEK - placebo)/placebo × 100.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">TCS Entire<br>Season </span></td>
<td class="Rrule" align="center">(629)<br>3.24</td>
<td class="Rrule" align="center">(672)<br>4.22</td>
<td class="Rrule" align="center" valign="bottom">-0.98</td>
<td class="Rrule" align="center">-23%<br>(-36.0, -13.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">TCS<br>Peak Season</span></td>
<td class="Rrule" align="center">(620)<br>3.33</td>
<td class="Rrule" align="center">(663)<br>4.67</td>
<td class="Rrule" align="center" valign="bottom">-1.33</td>
<td class="Rrule" align="center">-29%<br>(-39.0, -15.0)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS Entire<br>Season </span></td>
<td class="Rrule" align="center">(629)<br>2.49</td>
<td class="Rrule" align="center">(672)<br>3.13</td>
<td class="Rrule" align="center" valign="bottom">-0.64</td>
<td class="Rrule" align="center">-20%<br>(-32.0, -10.0)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">DMS Entire<br>Season </span></td>
<td class="Rrule" align="center">(629)<br>0.88</td>
<td class="Rrule" align="center">(672)<br>1.36</td>
<td class="Rrule" align="center" valign="bottom">-0.48</td>
<td class="Rrule" align="center">-35%<br>(-49.3, -20.8)</td>
</tr>
</tbody>
</table>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.1.2"></a><p></p>
<p class="First"><span class="Underline">Children</span></p>
<p>This double-blind clinical trial of approximately 24 weeks duration evaluated 344 pediatric subjects 5 to 17 years of age who were treated with either GRASTEK or placebo once daily. The subject population was 88% White, 7% African American, and 2% Asian. The majority (65%) of subjects were male. The mean age of subjects was 12.3 years. In this study, 26% of subjects had mild intermittent <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> and most subjects (89%) were sensitized to other allergens in addition to grass pollen. Subjects with a clinical history of symptomatic allergies to non-grass pollen allergens that required treatment during the grass pollen season were excluded from the studies. All treatment groups were balanced with regard to baseline characteristics.</p>
<p>Pediatric subjects treated with GRASTEK had a decrease in TCS throughout the grass pollen season compared to placebo treated subjects (see <a href="#table4">Table 4</a>). Similarly, the DSS and DMS were decreased in GRASTEK compared to placebo throughout the grass pollen season.</p>
<a name="table4"></a><table width="85%">
<caption><span>Table 4: Total Combined Scores (TCS), Rhinoconjunctivitis Daily Symptom Scores (DSS) and Daily Medication Scores (DMS) During the Entire Grass Pollen Season</span></caption>
<col align="left" valign="middle" width="17%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="19%">
<col align="center" valign="middle" width="24%">
<col align="center" valign="middle" width="21%">
<thead><tr class="First Last">
<th class="Lrule Rrule" align="left">Endpoint<a name="footnote-reference-5" href="#footnote-5" class="Sup">*</a>
</th>
<th class="Rrule" align="center">GRASTEK<br>(N=149)<a name="footnote-reference-6" href="#footnote-6" class="Sup">†</a><br>Score<a name="footnote-reference-7" href="#footnote-7" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Placebo<br>(N=158)<a href="#footnote-6" class="Sup">†</a><br>Score<a href="#footnote-7" class="Sup">‡</a>
</th>
<th class="Rrule" align="center">Treatment Difference <br>(GRASTEK – Placebo)</th>
<th class="Rrule" align="center">Difference Relative to Placebo<a name="footnote-reference-8" href="#footnote-8" class="Sup">§</a><br>Estimate<br>(95% CI)</th>
</tr></thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">TCS=Total combined score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-5" href="#footnote-reference-5">*</a></dt>
<dd>Parametric analysis using analysis of variance model for all endpoints.</dd>
<dt><a name="footnote-6" href="#footnote-reference-6">†</a></dt>
<dd>Number of subjects in analyses.</dd>
<dt><a name="footnote-7" href="#footnote-reference-7">‡</a></dt>
<dd>The estimated group means are reported and difference relative to placebo is based on estimated group means.</dd>
<dt><a name="footnote-8" href="#footnote-reference-8">§</a></dt>
<dd>Difference relative to placebo computed as: (GRASTEK - placebo)/placebo × 100.</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">TCS</span></td>
<td class="Rrule" align="center">
<br>4.62</td>
<td class="Rrule" align="center">
<br>6.25</td>
<td class="Rrule" align="center">
<br>-1.63 </td>
<td class="Rrule" align="center">-26%<br>(-38.2, -10.1)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">DSS</span></td>
<td class="Rrule" align="center">
<br>3.71</td>
<td class="Rrule" align="center">
<br>4.91</td>
<td class="Rrule" align="center">
<br>-1.20 </td>
<td class="Rrule" align="center">-24%<br>(-36.4, -9.1)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left" valign="middle"><span class="Bold">DMS</span></td>
<td class="Rrule" align="center">
<br>0.91</td>
<td class="Rrule" align="center">
<br>1.33</td>
<td class="Rrule" align="center">
<br>-0.42 </td>
<td class="Rrule" align="center">-32%<br>(-57.7, 4.0)</td>
</tr>
</tbody>
</table>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="s14.2"></a><a name="section-11.2"></a><p></p>
<h2>14.2	Sustained Effect</h2>
<div class="Section" data-sectionCode="42229-5">
<a name="section-11.2.1"></a><p></p>
<p class="First"><span class="Underline">Adult Subjects 18 Years and Older</span></p>
<p>The sustained effect of GRASTEK was measured in a 5-year double-blind study. The study included 634 randomized subjects between 18 and 65 years of age. The subject population was 96% White, 2% Asian and 1% African American. The majority (59%) of subjects were male. The mean age of subjects was 34 years. Subjects received either GRASTEK or placebo daily for 3 consecutive years and were then observed for 2 subsequent years during which they did not receive study drug. Subjects treated with GRASTEK had a decrease in TCS throughout the grass pollen season during the three years of active treatment. This effect was sustained during the grass pollen season in the first year after discontinuation of GRASTEK (see <a href="#table5">Table 5</a>), but not in the second year.</p>
<a name="table5"></a><table width="100%">
<caption><span>Table 5: Rhinoconjunctivitis Total Combined Score (TCS), Daily Symptom Score (DSS), and Daily Medication Score (DMS) During the Entire Grass Pollen Season from the 5-Year Study</span></caption>
<col align="left" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<col align="center" valign="middle" width="20%">
<thead>
<tr class="Botrule First">
<th class="Lrule Rrule" align="left" rowspan="2" valign="bottom">Endpoint</th>
<th class="Rrule" align="center" colspan="4">Difference Relative to Placebo<a name="footnote-reference-9" href="#footnote-9" class="Sup">*</a><br>(95% CI)</th>
</tr>
<tr class="Last">
<th class="Rrule" align="center">Treatment<br>Year 1<br><br>N=568<a name="footnote-reference-10" href="#footnote-10" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Treatment<br>Year 2<a name="footnote-reference-11" href="#footnote-11" class="Sup">‡</a><br><br>N=316<a href="#footnote-10" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Treatment<br>Year 3<br><br>N=287<a href="#footnote-10" class="Sup">†</a>
</th>
<th class="Rrule" align="center">Post Treatment<br>Year 1<br><br>N=257<a href="#footnote-10" class="Sup">†</a>
</th>
</tr>
</thead>
<tfoot>
<tr class="First Last"><td align="left" colspan="5">TCS=Total Combined Score (DSS + DMS); DSS=Daily Symptom Score; DMS=Daily Medication Score.</td></tr>
<tr><td colspan="5" align="left"><dl class="Footnote">
<dt><a name="footnote-9" href="#footnote-reference-9">*</a></dt>
<dd>Difference relative to placebo computed as: (GRASTEK - placebo)/placebo × 100.</dd>
<dt><a name="footnote-10" href="#footnote-reference-10">†</a></dt>
<dd>Number of subjects in analyses.</dd>
<dt><a name="footnote-11" href="#footnote-reference-11">‡</a></dt>
<dd>Study extended from 1 to 5 years (site closures, subject unwillingness to participate beyond 1 year).</dd>
</dl></td></tr>
</tfoot>
<tbody>
<tr class="Botrule First">
<td class="Lrule Rrule" align="left"><span class="Bold">TCS</span></td>
<td class="Rrule" align="center">-34.2%<br>(-42.0%, -26.3%)</td>
<td class="Rrule" align="center">-40.9%<br>(-51.8%, -29.5%)</td>
<td class="Rrule" align="center">-34.0%<br>(-45.5%, -21.4%)</td>
<td class="Rrule" align="center">-27.2%<br>(-39.9%, -12.4%)</td>
</tr>
<tr class="Botrule">
<td class="Lrule Rrule" align="left"><span class="Bold">DSS</span></td>
<td class="Rrule" align="center">-31.2%<br>(-38.8%, -23.4%)</td>
<td class="Rrule" align="center">-36.2%<br>(-46.5%, -26.2%)</td>
<td class="Rrule" align="center">-29.0%<br>(-40.3%, -16.3%)</td>
<td class="Rrule" align="center">-26.2%<br>(-37.6%, -12.2%)</td>
</tr>
<tr class="Last">
<td class="Lrule Rrule" align="left"><span class="Bold">DMS</span></td>
<td class="Rrule" align="center">-38.4%<br>(-49.8%, -26.5%)</td>
<td class="Rrule" align="center">-45.5%<br>(-60.4%, -28.2%)</td>
<td class="Rrule" align="center">-40.1%<br>(-55.4%, -21.2%)</td>
<td class="Rrule" align="center">-28.6%<br>(-46.3%, -6.0%)</td>
</tr>
</tbody>
</table>
</div>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="S16"></a><a name="section-12"></a><p></p>
<h1>16 HOW SUPPLIED/STORAGE AND HANDLING</h1>
<p class="First">GRASTEK 2800 BAU tablets are white to off-white, circular sublingual tablets with a debossed round detail on one side.</p>
<p>GRASTEK is supplied as follows:</p>
<p>3 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> packages of 10 tablets (30 tablets total). NDC 0006-4229-30</p>
<div class="Section" data-sectionCode="44425-7">
<a name="section-12.1"></a><p></p>
<p class="First">Store at controlled room temperature 20ºC-25ºC (68ºF-77ºF); excursions permitted between 15ºC-30ºC (59ºF-86ºF). Store in the original package until use to protect from moisture.</p>
</div>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="S17"></a><a name="section-13"></a><p></p>
<h1>17 PATIENT COUNSELING INFORMATION</h1>
<p class="First">Advise patients to read the FDA-approved patient labeling (Medication Guide) and to keep GRASTEK and all medicines out of the reach of children.</p>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.1"></a><p></p>
<p class="First"><span class="Underline">Severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergic Reactions</span></span></p>
<p>Advise patients that GRASTEK may cause life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span>, including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. Educate patients about the signs and symptoms of these <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> <span class="Italics">[See <a href="#s5.1">Warnings and Precautions (5.1)</a>.].</span> The signs and symptoms of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> may include: <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="316447" conceptname="Chronic hypotension">hypotension</span>, <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="314754" conceptname="Wheezing">wheezing</span>, <span class="product-label-link" type="condition" conceptid="256717" conceptname="Bronchospasm">bronchospasm</span>, <span class="product-label-link" type="condition" conceptid="4133044" conceptname="Chest discomfort">chest discomfort</span>, <span class="product-label-link" type="condition" conceptid="254761" conceptname="Cough">cough</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span>, <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="4169287" conceptname="Itching of skin">pruritus</span>, <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span>, and <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>.</p>
<p>Ensure that patients have auto-injectable epinephrine and instruct patients in its proper use. Instruct patients who experience a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to seek immediate medical care, discontinue GRASTEK, and resume treatment only when advised by a physician to do so. <span class="Italics">[See <a href="#s5.2">Warnings and Precautions (5.2)</a></span>.<span class="Italics">]</span></p>
<p>Advise patients to read the patient information for epinephrine.</p>
<p>Inform patients that the first dose of GRASTEK must be administered in a healthcare setting under the supervision of a physician and that they will be monitored for at least 30 minutes to watch for signs and symptoms of a life-threatening systemic or local <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> <span class="Italics">[See <a href="#s5.1">Warnings and Precautions (5.1)</a>.]</span></p>
<p>Because of the risk of upper airway compromise, instruct patients with persistent and escalating adverse reactions in the mouth or throat to discontinue GRASTEK and to contact their healthcare professional. <span class="Italics">[See <a href="#s5.3">Warnings and Precautions (5.3)</a>].</span></p>
<p>Because of the risk of eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>, instruct patients with severe or persistent symptoms of <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span> to discontinue GRASTEK and to contact their healthcare professional. <span class="Italics">[See <a href="#s5.4">Warnings and Precautions (5.4)</a>].</span></p>
<p>Inform parents/guardians that GRASTEK should only be administered to children under adult supervision <span class="Italics">[See <a href="#s2.2">Dosage and Administration (2.2)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.2"></a><p></p>
<p class="First"><span class="Underline"><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span></span></p>
<p>Instruct patients with <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> that if they have <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">difficulty breathing</span> or if their <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span> becomes difficult to control, they should stop taking GRASTEK and contact their healthcare professional immediately <span class="Italics">[See <a href="#s5.5">Warnings and Precautions (5.5)</a>]</span>.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-13.3"></a><p></p>
<p class="First"><span class="Underline">Administration Instructions</span></p>
<p>Instruct patients to carefully remove the foil from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> unit with dry hands and then take the sublingual tablet immediately by placing it under the tongue where it will dissolve. Also instruct patients to wash their hands after handling the tablet, and to avoid food or beverages for 5 minutes after taking the tablet. <span class="Italics">[See <a href="#s2.2">Dosage and Administration (2.2)</a>.]</span></p>
</div>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-14"></a><p></p>
<p class="First">Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by: <br>Catalent Pharma Solutions Limited, Blagrove,<br>Swindon, Wiltshire, SN5 8RU UK</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>uspi-mk7243-sb-1406r001</p>
</div>
<div class="Section" data-sectionCode="42231-1">
<a name="section-15"></a><p></p>
<h1>MEDICATION GUIDE</h1>
<p class="First"><span class="Bold">GRASTEK<span class="Sup">®</span> (GRAS-tek)</span></p>
<p><span class="Bold">(Timothy Grass Pollen Allergen Extract)</span></p>
<p>Carefully read this Medication Guide before you or your child start taking GRASTEK and each time you get a refill. This Medication Guide does not take the place of talking to your doctor about your medical condition or treatment. Talk with your doctor or pharmacist if there is something you do not understand or you want to learn more about GRASTEK.</p>
<p><a name="important-info"></a><span class="Bold">What is the Most Important Information I Should Know about GRASTEK?</span></p>
<p>GRASTEK can cause severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be life-threatening. Stop taking GRASTEK and get medical treatment right away if you or your child has any of the following symptoms after taking GRASTEK:</p>
<ul class="Disc">
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li>Trouble swallowing or speaking</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
</ul>
<p>For home administration of GRASTEK, your doctor will prescribe auto-injectable epinephrine, a medicine you can inject if you or your child has a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> after taking GRASTEK. Your doctor will train and instruct you on the proper use of auto-injectable epinephrine.</p>
<p>Talk to your doctor or read the epinephrine patient information if you have any questions about the use of auto-injectable epinephrine.</p>
<p><span class="Bold">What is GRASTEK?</span></p>
<p>GRASTEK is a prescription medicine used for sublingual (under the tongue) immunotherapy to treat Timothy and related grass pollen allergies that can cause <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, runny or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> nose, stuffy or congested nose, or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itchy</span> and watery eyes. GRASTEK may be prescribed for persons 5 through 65 years of age who are allergic to grass pollen.</p>
<p>GRASTEK is taken for about 12 weeks before grass pollen season and throughout grass pollen season. GRASTEK may also be taken daily for 3 years to provide a sustained effect for a fourth year in which you do not have to take GRASTEK.</p>
<p>GRASTEK is NOT a medication that gives immediate relief for symptoms of grass <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span>.</p>
<p><a name="who-should-not"></a><span class="Bold">Who Should Not Take GRASTEK?</span></p>
<p>You or your child should not take GRASTEK if:</p>
<ul>
<li>You or your child has severe, unstable or uncontrolled <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span></li>
<li>You or your child had a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> in the past that included any of these symptoms: 						<ul class="Circle">
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
</ul>
</li>
<li>You or your child has ever had difficulty with breathing due to <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the throat or upper airway after using any sublingual immunotherapy before.</li>
<li>You or your child has ever been diagnosed with eosinophilic <span class="product-label-link" type="condition" conceptid="30753" conceptname="Esophagitis">esophagitis</span>.</li>
<li>You or your child is allergic to any of the inactive ingredients contained in GRASTEK. The inactive ingredients contained in GRASTEK are: gelatin, mannitol and sodium hydroxide.</li>
</ul>
<p><span class="Bold">What Should I Tell My Doctor Before Taking GRASTEK?</span></p>
<p>Your doctor may decide that GRASTEK is not the best treatment if:</p>
<ul>
<li>You or your child has <span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">asthma</span>, depending on how severe it is.</li>
<li>You or your child suffers from <span class="product-label-link" type="condition" conceptid="257907" conceptname="Disorder of lung">lung disease</span> such as <span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">chronic obstructive pulmonary disease</span> (<span class="product-label-link" type="condition" conceptid="255573" conceptname="Chronic obstructive lung disease">COPD</span>)</li>
<li>You or your child suffers from heart disease such as <span class="product-label-link" type="condition" conceptid="317576" conceptname="Coronary arteriosclerosis">coronary artery disease</span>, an irregular heart rhythm, or you have <span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">hypertension</span> that is not well controlled.</li>
<li>You or your daughter is pregnant, plans to become pregnant during the time you will be taking GRASTEK, or is breast-feeding.</li>
<li>You or your child is unable or unwilling to administer auto-injectable epinephrine to treat a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> to GRASTEK.</li>
<li>You or your child is taking certain medicines that enhance the likelihood of a severe reaction, or interfere with the treatment of a severe reaction. These medicines include: 						<ul class="Circle">
<li>beta blockers and alpha-blockers (prescribed for high blood pressure)</li>
<li>cardiac glycosides (prescribed for <span class="product-label-link" type="condition" conceptid="316139" conceptname="Heart failure">heart failure</span> or problems with heart rhythm)</li>
<li>diuretics (prescribed for heart conditions and high blood pressure)</li>
<li>ergot alkaloids (prescribed for <span class="product-label-link" type="condition" conceptid="318736" conceptname="Migraine">migraine headache</span>)</li>
<li>monoamine oxidase inhibitors or tricyclic antidepressants (prescribed for <span class="product-label-link" type="condition" conceptid="438727" conceptname="Atypical depressive disorder">depression</span>)</li>
<li>thyroid hormone (prescribed for low thyroid activity).</li>
</ul>
</li>
<li>You or your child is receiving <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergy</span> shots or other immunotherapy under the tongue. Use of more than one of these types of medicines together may increase the likelihood of a severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</li>
</ul>
<p>You should tell your doctor if you or your child is taking or has recently taken any other medicines, including medicines obtained without a prescription and herbal supplements. Keep a list of them and show it to your doctor and pharmacist each time you get a new supply of GRASTEK. Ask your doctor or pharmacist for advice before taking GRASTEK.</p>
<p><a name="stop-taking"></a><span class="Bold">Are there any reasons to stop taking GRASTEK?</span></p>
<p>Stop GRASTEK and contact your doctor if you or your child has any of the following after taking GRASTEK:</p>
<ul>
<li>Any type of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span></li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> that worsens or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> of the tongue or throat that causes trouble speaking, breathing or swallowing</li>
<li><span class="product-label-link" type="condition" conceptid="317009" conceptname="Asthma">Asthma</span> or any other breathing condition that gets worse</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
<li><span class="product-label-link" type="condition" conceptid="23325" conceptname="Heartburn">Heartburn</span>, difficulty swallowing, <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span> with swallowing, or <span class="product-label-link" type="condition" conceptid="77670" conceptname="Chest pain">chest pain</span> that does not go away or worsens</li>
</ul>
<p>Also, stop taking GRASTEK following: mouth surgery procedures (such as tooth removal), or if you develop any mouth <span class="product-label-link" type="condition" conceptid="432250" conceptname="Infectious disease">infections</span>, <span class="product-label-link" type="condition" conceptid="4177703" conceptname="Ulcer">ulcers</span> or cuts in the mouth or throat.</p>
<p><a name="how-take"></a><span class="Bold">How should I take GRASTEK?</span></p>
<p>Take GRASTEK exactly as your doctor tells you.</p>
<p>GRASTEK is a prescription medicine that is placed under the tongue.</p>
<ul>
<li>Take the tablet from the <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> package after carefully removing the foil with dry hands.</li>
<li>Place the tablet immediately under the tongue. Allow it to remain there until completely dissolved. Do not swallow for at least 1 minute.</li>
<li>Do not take GRASTEK with food or beverage. Food and beverage should not be taken for the following 5 minutes.</li>
<li>Wash hands after taking the tablet.</li>
</ul>
<p>Take the first tablet of GRASTEK in your doctor's office. After taking the first tablet, you or your child will be watched for at least 30 minutes for symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>. </p>
<p>If you tolerate the first dose of GRASTEK, you or your child will continue GRASTEK therapy at home by taking one tablet every day. Children should be given each tablet of GRASTEK by an adult who will watch for any symptoms of a serious <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span>.</p>
<p>Take GRASTEK as prescribed by your doctor until the end of the treatment course. If you forget to take GRASTEK, do not take a double dose. Take the next dose at your normal scheduled time the next day. If you miss more than one dose of GRASTEK, contact your healthcare provider before restarting.</p>
<p><a name="possible-side-effects"></a><span class="Bold">What are the possible side effects of GRASTEK?</span></p>
<p>In children and adults, the most commonly reported side effects were <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the mouth, lips, or tongue, <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span> under the tongue, or <span class="product-label-link" type="condition" conceptid="4038048" conceptname="Throat irritation">throat irritation</span>. These side effects, by themselves, were not dangerous or life-threatening.</p>
<p>GRASTEK can cause severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> that may be life-threatening. Symptoms of <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reactions</span> to GRASTEK include:</p>
<ul>
<li>Trouble breathing</li>
<li><span class="product-label-link" type="condition" conceptid="4194507" conceptname="Feeling of throat tightness">Throat tightness</span> or <span class="product-label-link" type="condition" conceptid="4275722" conceptname="Swelling">swelling</span></li>
<li>Trouble swallowing or speaking</li>
<li><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span> or <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">fainting</span></li>
<li>Rapid or weak heartbeat</li>
<li>Severe <span class="product-label-link" type="condition" conceptid="194175" conceptname="Left upper quadrant pain">stomach cramps</span> or <span class="product-label-link" type="condition" conceptid="4329041" conceptname="Pain">pain</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, or <span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">diarrhea</span></li>
<li>Severe <span class="product-label-link" type="condition" conceptid="318566" conceptname="Flushing">flushing</span> or <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span> of the skin</li>
</ul>
<p>For additional information on the possible side effects of GRASTEK, talk with your doctor or pharmacist. You may report side effects to the U.S. Food and Drug Administration (FDA) at 1-800-FDA-1088 or www.fda.gov/medwatch.</p>
<p><a name="how-store"></a><span class="Bold">How should I store GRASTEK?</span></p>
<p>Keep GRASTEK out of the reach of children.</p>
<p>Throw away any unused GRASTEK after the expiration date which is stated on the carton and <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> pack after "EXP."</p>
<p>Store GRASTEK in a dry place at room temperature, 15ºC to 30ºC (59ºF to 86ºF), in the original package.</p>
<p><span class="Bold">General information about GRASTEK</span></p>
<p>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use GRASTEK for a condition for which it was not prescribed. Do not give GRASTEK to other people, even if they have the same symptoms. It may harm them.</p>
<p>This Medication Guide summarizes the most important information about GRASTEK. If you would like more information, talk with your doctor. You can ask your doctor or pharmacist for information about GRASTEK that was written for healthcare professionals. For more information go to www.grastek.com or call toll-free at 1-800-622-4477.</p>
<p><span class="Bold">This Medication Guide has been approved by the U.S. Food and Drug Administration.</span></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="section-16"></a><p></p>
<p class="First">Manufactured for: Merck Sharp &amp; Dohme Corp., a subsidiary of <br><span class="Bold">MERCK &amp; CO., INC.,</span> Whitehouse Station, NJ 08889, USA</p>
<p>Manufactured by: <br>Catalent Pharma Solutions Limited, Blagrove,<br>Swindon, Wiltshire, SN5 8RU UK</p>
<p>For patent information: www.merck.com/product/patent/home.html</p>
<p>Copyright © 2014 Merck Sharp &amp; Dohme Corp., a subsidiary of <span class="Bold">Merck &amp; Co., Inc.</span><br>All rights reserved.</p>
<p>Revised: 02/2015</p>
<p>usmg-mk7243-sb-1502r001</p>
</div>
<div class="Section" data-sectionCode="51945-4">
<a name="section-17"></a><p></p>
<h1>PRINCIPAL DISPLAY PANEL - 3 x 10-Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card Carton</h1>
<p class="First">NDC 0006-4229-30<br>This carton contains 30 sublingual tablets in three 10-Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">blister</span> cards</p>
<p><span class="Bold">Timothy Grass Pollen Allergen Extract,<br>Grastek<span class="Sup">® </span>Tablet for sublingual use</span></p>
<p><span class="Bold">2800 BAU</span></p>
<p>For Adults and Children 5 to 65 Years of Age<br>Each Grastek tablet contains 2800 Bioequivalent <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">Allergy</span> Units (BAUs) of timothy grass pollen<br>allergen extract.<br>Dispense the enclosed Medication Guide to the patient.<br><span class="Bold">Keep this and all drugs out of the reach of children.</span></p>
<p><span class="Bold">Rx only</span></p>
<div class="Figure"><img alt="Principal Display Panel - 3 x 10-Tablet <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">Blister</span> Card Carton" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=1d7f3e56-c233-47a4-9bcd-80098ffff47d&amp;name=grastek-01.jpg"></div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>GRASTEK 		
					</strong><br><span class="contentTableReg">timothy grass pollen allergen extract tablet</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">STANDARDIZED ALLERGENIC</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:0006-4229</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">SUBLINGUAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>PHLEUM PRATENSE POLLEN</strong> (PHLEUM PRATENSE POLLEN) </td>
<td class="formItem">PHLEUM PRATENSE POLLEN</td>
<td class="formItem">2800 [BAU]</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>MARINE COLLAGEN, SOLUBLE</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>MANNITOL</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>SODIUM HYDROXIDE</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Characteristics</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Color</td>
<td class="formItem">WHITE (white to off-white) </td>
<td class="formLabel">Score</td>
<td class="formItem">no score</td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Shape</td>
<td class="formItem">ROUND</td>
<td class="formLabel">Size</td>
<td class="formItem">13mm</td>
</tr>
<tr class="formTableRowAlt">
<td class="formLabel">Flavor</td>
<td class="formItem"></td>
<td class="formLabel">Imprint Code</td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<td class="formLabel">Contains</td>
<td class="formItem">    </td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-4229-30</td>
<td class="formItem">3  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:0006-4229-01</td>
<td class="formItem">10  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem">NDC:0006-4229-02</td>
<td class="formItem">1  in 1 CARTON</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
<tr class="formTableRow">
<th scope="row" class="formItem">2</th>
<td class="formItem"></td>
<td class="formItem">5  in 1 <span class="product-label-link" type="condition" conceptid="443720" conceptname="Blister">BLISTER</span> PACK; Combination Product Type = C112160</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"><table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Marketing Information</span></td></tr>
<tr>
<th scope="col" class="formTitle">Marketing Category</th>
<th scope="col" class="formTitle">Application Number or Monograph Citation</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">BLA</td>
<td class="formItem">BLA125473</td>
<td class="formItem">04/11/2014</td>
<td class="formItem"></td>
</tr>
</table></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>Merck Sharp &amp; Dohme Corp.
							(001317601)
						</td></tr></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Catalent Pharma Solutions Limited</td>
<td class="formItem"></td>
<td class="formItem">237676320</td>
<td class="formItem">MANUFACTURE(0006-4229)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">ALK-Abello A S</td>
<td class="formItem"></td>
<td class="formItem">306020926</td>
<td class="formItem">API MANUFACTURE(0006-4229)</td>
</tr>
</table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite">
<tr><td colspan="4" class="formHeadingReg"><span class="formHeadingTitle">Establishment</span></td></tr>
<tr>
<th scope="col" class="formTitle">Name</th>
<th scope="col" class="formTitle">Address</th>
<th scope="col" class="formTitle">ID/FEI</th>
<th scope="col" class="formTitle">Business Operations</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">Merck Sharp &amp; Dohme Corp.</td>
<td class="formItem"></td>
<td class="formItem">101740835</td>
<td class="formItem">PACK(0006-4229)</td>
</tr>
</table>
</div>
<p><div class="EffectiveDate">Revised: 2/2015<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>8860167a-df4b-418c-8491-a0ce353b7309</div>
<div>Set id: 1d7f3e56-c233-47a4-9bcd-80098ffff47d</div>
<div>Version: 5</div>
<div>Effective Time: 20150213</div>
</div>
</div> <div class="DistributorName">Merck Sharp &amp; Dohme Corp.</div></p>
</body></html>
